{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:18:47Z","timestamp":1792793927288,"version":"4.5.0"},"reference-count":41,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Introduction: Cardiac amyloidosis, primarily comprising transthyretin amyloid cardiomyopathy (ATTR-CM) and light-chain amyloidosis with cardiac involvement (AL-cardiac), is an increasingly recognized contributor to the global heart failure burden. Management has shifted from supportive care to disease-modifying agents targeting specific stages of the amyloid cascade. This registry-based review qualitatively characterizes the current pharmacological clinical trial landscape through a registry-based analysis. Methods: A structured qualitative analysis of ClinicalTrials.gov was conducted for interventional trials registered between January 2015 and November 2025. Following PRISMA principles, studies were screened to include pharmacological interventions with explicit cardiac targeting while excluding neuropathy-dominant amyloidosis. Trial-level data regarding therapeutic classes, study phases, enrollment, and primary outcome domains were extracted and synthesized. Results: A total of 18 trials met the inclusion criteria (14 ATTR-CM; 4 AL-cardiac), representing a total enrollment of 4924 participants across 11 unique agents. Five therapeutic classes were identified: amyloid-clearing monoclonal antibodies (44.4% of trials), TTR silencers, TTR stabilizers, fibril-modifying agents, and cardiac phenotype-directed therapies. Monoclonal antibodies represented the largest class by both trial count and enrollment (3075 participants). Clinical events (n = 7) and safety\/tolerability (n = 5) were the most frequent primary outcome domains. ATTR-CM trials dominated the landscape, accounting for 77.7% of the total study population, while parallel-group placebo-controlled designs were the most common study architecture (n = 10). Conclusions: The therapeutic landscape for cardiac amyloidosis is transitioning toward stage-specific, mechanism-based interventions. While ATTR-CM currently dominates research efforts, the expansion of silencers and monoclonal antibodies reflects an increasing capacity to intercept the amyloid cascade at distinct molecular checkpoints. However, significant heterogeneity in outcome measures and the shift toward diagnosing milder disease pose challenges for demonstrating clinical efficacy. Future priorities include standardized progression markers and addressing barriers to global access for these high-cost therapies.<\/jats:p>","DOI":"10.3390\/jcm15041499","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:38:39Z","timestamp":1771231119000},"page":"1499","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Emerging Pharmacological Strategies for Cardiac Amyloidosis: A Qualitative Analysis of Interventional Clinical Trials Registered on ClinicalTrials.Gov"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8892-5192","authenticated-orcid":false,"given":"Maan H.","family":"Harbi","sequence":"first","affiliation":[{"name":"Pharmacology and Toxicology Department, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahya A.","family":"Alzahrani","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, King Abdulaziz University, Rabigh 25732, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"ref_2","first-page":"e14177","article-title":"Hospitalization Rates, Prevalence of Cardiovascular Manifestations and Outcomes Associated With Amyloidosis in the United States","volume":"13","author":"Oladiran","year":"2021","journal-title":"Cureus"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"ref_4","first-page":"1","article-title":"Cardiac Amyloidosis: Clinical Features, Pathogenesis, Diagnosis, and Treatment","volume":"40","author":"Argon","year":"2024","journal-title":"Turk. Patoloji Derg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/13506129.2018.1549825","article-title":"Amyloid nomenclature 2018: Recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"25","author":"Benson","year":"2018","journal-title":"Amyloid"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e012112","DOI":"10.1161\/CIRCHEARTFAILURE.124.012112","article-title":"Changing Treatment Landscape in Transthyretin Cardiac Amyloidosis","volume":"18","author":"Fontana","year":"2025","journal-title":"Circ. Heart Fail."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Porcari, A., Allegro, V., Saro, R., Varr\u00e0, G.G., Pagura, L., Rossi, M., Lalario, A., Longo, F., Korcova, R., and Dal Ferro, M. (2022). Evolving trends in epidemiology and natural history of cardiac amyloidosis: 30-year experience from a tertiary referral center for cardiomyopathies. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.1026440"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijcard.2021.04.023","article-title":"Changes in the perceived epidemiology of amyloidosis: 20 year-experience from a Tertiary Referral Centre in Tuscany","volume":"335","author":"Zampieri","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Saleem, M., Sadat, B., Harn, M.V., and Ananthasubramaniam, K. (2023). Towards a Diagnosis of Cardiac Amyloidosis: Single Center Experience With 99m Technetium Pyrophosphate Planar Imaging and Opportunities for Standardization of Diagnostic Workflow. Medicina, 59.","DOI":"10.3390\/medicina59020378"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/eurheartj\/ehaf667","article-title":"Transthyretin amyloid cardiomyopathy: From cause to novel treatments","volume":"47","author":"Fontana","year":"2026","journal-title":"Eur. Heart J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.15420\/usc.2025.11","article-title":"Transthyretin Amyloid Cardiomyopathy: The Plot Thickens as Novel Therapies Emerge","volume":"19","author":"Dimza","year":"2025","journal-title":"US Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/eurheartj\/ehp596","article-title":"The role of cardiac registries in evidence-based medicine","volume":"31","author":"Gitt","year":"2010","journal-title":"Eur. Heart J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e007963","DOI":"10.1161\/CIRCOUTCOMES.121.007963","article-title":"Characteristics and Quality of National Cardiac Registries: A Systematic Review","volume":"14","author":"Dawson","year":"2021","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.14797\/mdcj-16-3-205","article-title":"The Role of National Registries in Improving Quality of Care and Outcomes for Cardiovascular Disease","volume":"16","author":"Meltzer","year":"2020","journal-title":"Methodist. Debakey Cardiovasc. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/13506129.2016.1148025","article-title":"Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin","volume":"23","author":"Higaki","year":"2016","journal-title":"Amyloid"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1479-5876-8-74","article-title":"Synergy of combined doxycycline\/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: Studies in FAP mouse models","volume":"8","author":"Cardoso","year":"2010","journal-title":"J. Transl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Rapezzi","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Senigarapu, S., and Driscoll, J.J. (2024). A review of recent clinical trials to evaluate disease-modifying therapies in the treatment of cardiac amyloidosis. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1477988"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/ejh.13681","article-title":"Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement","volume":"107","author":"Oubari","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"37893","DOI":"10.1038\/s41598-025-21779-9","article-title":"Applicability of phase 3 trial selection criteria to real-world transthyretin amyloid cardiomyopathy patients","volume":"15","author":"Poledniczek","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e009038","DOI":"10.1161\/CIRCHEARTFAILURE.121.009038","article-title":"Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group","volume":"15","author":"Maurer","year":"2022","journal-title":"Circ. Heart Fail."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jcmg.2024.11.003","article-title":"Development of Imaging Endpoints for Clinical Trials in AL and ATTR Amyloidosis: Proceedings of the Amyloidosis Forum","volume":"18","author":"Dorbala","year":"2025","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11897-024-00669-7","article-title":"Current Therapies and Future Horizons in Cardiac Amyloidosis Treatment","volume":"21","author":"Vogel","year":"2024","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC)","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis","volume":"81","author":"Kittleson","year":"2023","journal-title":"JACC"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"i88","DOI":"10.1093\/eurheartjsupp\/suae111","article-title":"Cardiac amyloidosis: Innovations in diagnosis and treatment","volume":"27","author":"Castiglione","year":"2025","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/ehf2.13443","article-title":"Progress and challenges in the treatment of cardiac amyloidosis: A review of the literature","volume":"8","author":"Adam","year":"2021","journal-title":"ESC Heart Fail."},{"key":"ref_29","first-page":"93","article-title":"Evolving Strategies in Cardiac Amyloidosis: From Mechanistic Discoveries to Diagnostic and Therapeutic Advances","volume":"43","author":"Swier","year":"2025","journal-title":"Cardiol. Clin."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.recesp.2017.05.018","article-title":"Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis","volume":"70","year":"2017","journal-title":"Progress and Hope. Rev. Esp. Cardiol. (Engl. Ed.)"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1161\/CIRCULATIONAHA.113.006242","article-title":"Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis","volume":"129","author":"Quarta","year":"2014","journal-title":"Circulation"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Nguyen, D.M., Ramazani, N., Sodhi, G., and Tak, T. (2025). Cardiac Amyloidosis: Tribulations and New Frontiers. J. Pers. Med., 15.","DOI":"10.3390\/jpm15100472"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2174\/011573403X240302230925043500","article-title":"Cardiac Amyloidosis: A Contemporary Review of Medical and Surgical Therapy","volume":"20","author":"Brownell","year":"2024","journal-title":"Curr. Cardiol. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/sj.bmt.1702643","article-title":"Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL)","volume":"26","author":"Gertz","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/jamacardio.2016.5864","article-title":"Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model","volume":"2","author":"Arvanitis","year":"2017","journal-title":"JAMA Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"106939","DOI":"10.1016\/j.medcli.2025.106939","article-title":"Biomarkers in transthyretin amyloidosis. Present and future","volume":"164","year":"2025","journal-title":"Med. Clin."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11897-025-00696-y","article-title":"Biomarkers in Subclinical Transthyretin Cardiac Amyloidosis","volume":"22","author":"Gulati","year":"2025","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_39","first-page":"1801","article-title":"A simplified cardiac amyloidosis score predicts all-cause and cardiovascular disease mortality and morbidity in the general population: The Ikaria Study","volume":"21","author":"Chrysohoou","year":"2025","journal-title":"Arch. Med. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ehf2.15147","article-title":"Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing-A multicentre study","volume":"12","author":"Willixhofer","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/ejhf.2606","article-title":"Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis","volume":"24","author":"Chacko","year":"2022","journal-title":"Eur. J. Heart Fail."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/4\/1499\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:53:35Z","timestamp":1771232015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/4\/1499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["jcm15041499"],"URL":"https:\/\/doi.org\/10.3390\/jcm15041499","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]}}}